Super-resolution microscopy reveals functional organization of dopamine transporters into cholesterol and neuronal activity-dependent nanodomains

Troels Rahbek-Clemmensen1,2, Matthew D. Lycas1, Simon Erlendsson1, Jacob Eriksen1,2, Mia Apuschkin1, Frederik Vilhardt3, Trine N. Jørgensen1, Freja H. Hansen1 & Ulrik Gether1,2

Dopamine regulates reward, cognition, and locomotor functions. By mediating rapid reuptake of extracellular dopamine, the dopamine transporter is critical for spatiotemporal control of dopaminergic neurotransmission. Here, we use super-resolution imaging to show that the dopamine transporter is dynamically sequestrated into cholesterol-dependent nanodomains in the plasma membrane of presynaptic varicosities and neuronal projections of dopaminergic neurons. Stochastic optical reconstruction microscopy reveals irregular dopamine transporter nanodomains (∼70 nm mean diameter) that were highly sensitive to cholesterol depletion. Live photoactivated localization microscopy shows a similar dopamine transporter membrane organization in live heterologous cells. In neurons, dual-color dSTORM shows that tyrosine hydroxylase and vesicular monoamine transporter-2 are distinctively localized adjacent to, but not overlapping with, the dopamine transporter nanodomains. The molecular organization of the dopamine transporter in nanodomains is reversibly reduced by short-term activation of NMDA-type ionotropic glutamate receptors, implicating dopamine transporter nanodomain distribution as a potential mechanism to modulate dopaminergic neurotransmission in response to excitatory input.

1Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark. 2Lundbeck Foundation Center for Biomembranes in Nanomedicine, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark. 3Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark. Correspondence and requests for materials should be addressed to U.G. (email: gether@sund.ku.dk)
To obtain a detailed understanding of cellular functions and how they may be altered in disease, it is essential to achieve insight into the spatial organization of the involved molecular components and how this architecture is regulated. The dopamine transporter (DAT), for example, is a key component of dopaminergic synapses, as it mediates rapid Na⁺-dependent reuptake of released dopamine from the terminals and thereby shapes the spatiotemporal profile of dopamine signaling. Consequently, tight control of both DAT distribution and activity in the dopaminergic neurons is critical for proper regulation of dopamine homeostasis and thus for governing the role of dopamine in cognition, reward and locomotor control.

Mechanisms underlying such regulation become even more important given that dysfunctional dopamine signaling has been linked to disorders such as Parkinson’s disease, attention deficit hyperactivity-disorder, schizophrenia, bipolar disorder, and drug addiction. Moreover, DAT is the primary target for psychostimulants such as cocaine and amphetamines.

Microscopic techniques have been pivotal for our understanding of cellular mechanisms that control the distribution of individual proteins at the subcellular level. Indeed, several methods have been applied to visualize DAT, including electron microscopy (EM) and multiple fluorescence microscopy (FM) approaches. Application of FM has permitted overall insight into constitutive and regulated trafficking of DAT (for review see Eriksen et al.), as well as it has reported abundant and generally uniform expression of DAT in dopaminergic neurons. EM studies similarly support that DAT is widely found in the plasma membrane of dopaminergic neurons with highest density in the plasma membrane of the axonal compartment. They also interestingly revealed that the transporter appears to be excluded from the active zones. Nevertheless, the important insights from EM and FM are potentially limited by low antibody labeling efficiency in EM studies, and the restricted resolution of FM. Accordingly, these approaches may have missed nanoscale heterogeneities in the subcellular distribution of the transporter that could be important for spatiotemporal control of its function. In this context it is interesting that DAT has been suggested to be sequestered into cholesterol- and glycosphingolipid-enriched plasma membrane microdomains (‘membrane rafts’) and that these have been proposed to serve as “hot spots” for regulation of transporter trafficking and function including amphetamine-induced dopamine release.

New super-resolution microscopy techniques offer a major improvement in the spatial resolution (down to 10 nm in the lateral direction), thereby enabling visualization of cellular structures at a resolution unprecedented by conventional fluorescence microscopy. Here, we employ photoactivated localization microscopy (PALM) and stochastic optical reconstruction microscopy (STORM) super-resolution microscopy to investigate the nanoscale localization of an endogenously expressed photoswitchable Dronpa-DAT in CAD cells. Dronpa-DAT often formed irregular clusters or “nanodomains” of various sizes as clearly seen when enlarging a region of the image (Fig. 1a, examples indicated by red arrows). Application of a density-based spatial clustering of applications with noise (DBSCAN) analysis, which has been used to assess clustering of other membrane proteins, substantiated a clear nanodomain pattern for DAT with a median cluster size of ~70 nm in diameter (Fig. 1d). Importantly, by application of the analysis recently published by Baumgart et al., we could rule out that these clusters are not the result of multiple observations of single fluorophores (Supplementary Fig. 1).

We next tested whether the nanodomain distribution seen for Dronpa-DAT was a general phenomenon for any membrane-associated protein. We analyzed Src15-Dronpa, consisting of the myristoylated N-terminus of p60SRC fused to Dronpa. This protein has been used as a marker of homogenous, non-raft plasma membrane and, in contrast to Dronpa-DAT, the PALM images revealed a much more homogenous distribution of the detected localization with a significant lower fraction of localizations in nanodomains (Fig. 1e–h, q). To investigate the nature of the Dronpa-DAT nanodomains, we extracted cholesterol from the plasma membrane using 5 mM methyl-β-cyclodextrin (mβCD) or disrupted the actin polymerization with 5 μM cytochalasin D (CytD). The TIRF-M revealed no apparent effect of mβCD on the Dronpa-DAT distribution; however, from the reconstructed PALM images and the DBSCAN quantification, we observed a more homogenous distribution of Dronpa-DAT and a clear reduction in the number of confined nanodomains (Fig. 1i, j, q). In contrast, CytD did not cause any apparent changes in the distribution of the Dronpa-DAT signal. As determined by a reversible biotinylation assay, the mβCD treatment had no effect on Dronpa-DAT internalization, indicating that the decreased nanodomain distribution was not caused by redistribution of the transporter away from the plasma membrane (Supplementary Fig. 2). To further confirm the role of cholesterol in the nanodomain distribution of Dronpa-DAT, we treated the Dronpa-DAT expressing CAD cells with nystatin, a cholesterol-binding polycry antibiotic, which can sequester cholesterol in the membrane and disrupt membrane rafts. The PALM images showed that nystatin, like mβCD,
Fig. 1 Dronpa-DAT distributes to cholesterol-dependent nanodomains in the plasma membrane of living CAD cells. a–d Images of untreated live CAD cells transiently expressing Dronpa-DAT. a TIRF-M image. b Reconstructed PALM image. c Enlarged PALM image corresponding to the boxed region in a, b. d DBSCAN-based cluster map of Dronpa-DAT distribution. Clustered localizations are shown by color-coding with non-clustered localizations in gray. e–h Images of live CAD cells expressing the myristoylated N-terminus of p60SRC fused to Dronpa (Src15-Dronpa). e TIRF-M image, f reconstructed PALM image. g Enlarged PALM image corresponding to the boxed region in e, f. h DBSCAN-based cluster map of Src15-Dronpa distribution. Clustered localizations are shown by color-coding with non-clustered localizations in gray. i–l Images of Dronpa-DAT expressing CAD cells treated with 5 mM methyl-β-cyclodextrin (mβCD) to remove cholesterol. i TIRF-M image, j reconstructed PALM image. k Enlarged PALM image corresponding to the boxed region in i, j. l DBSCAN-based cluster map of Dronpa-DAT distribution. m–p Images of Dronpa-DAT expressing CAD cells treated with 5 μg ml⁻¹ cytochalasin D (CytD) to disrupt the actin skeleton. m TIRF-M image, n reconstructed PALM image. o Enlarged PALM image corresponding to the boxed region in m, n. p DBSCAN-based cluster map of Dronpa-DAT distribution. q Clustering of Dronpa-DAT measured as the fraction in % of total localizations (mean ± s.e.m., *p < 0.05, one-way ANOVA with a Bonferroni’s post-test). Data are based on 12–20 cells from three independent experiments. Red arrows mark examples of DAT clustered in nanodomains. Scale bars a, b, e, f, i, j, m, n 5 μm, c, d, g, h, k, l, o, p 1 μm.
caused a significant decrease in the fraction of Dronpa-DAT in nanodomains (Supplementary Fig. 3).

The marked effect of cholesterol depletion on DAT distribution prompted us to test biochemically whether DAT expressed in CAD cells is distributed into detergent-resistant membrane fractions (i.e., the membrane raft fractions) in a cholesterol-dependent manner. CAD cells transiently expressing DAT were extracted with the non-ionic detergent Brij 58 and subjected to sucrose density gradient fractionation. Western blotting analysis of the resulting fractions showed that DAT was distributed in part to the detergent-resistant high buoyancy fractions identified by flotillin-1 (FLOT-1), a marker of membrane rafts29 (Supplementary Fig. 4a). DAT immunoactivity was also, as expected, found in the high-density fractions identified by the transferrin receptor (TIR) (Supplementary Fig. 4a). In correspondence with our PALM analysis, cholesterol depletion with mβCD prior to cell lysis, removed DAT immunoactivity from the detergent-resistant high buoyancy fractions, whereas CytD had no effect (Supplementary Fig. 4a). Of note, endogenous DAT solubilized from striatal extracts also distributed in part to the detergent-resistant high buoyancy fractions (Supplementary Fig. 4b).

**STORM also shows nanodomain distribution of DAT in CAD cells.** To demonstrate that the observed nanodomain distribution of DAT in CAD cells is not a result of fusing Dronpa to the N-terminus of the transporter, we also imaged DAT in CAD cells using STORM. STORM is based on immunolabeling with fluorescent conjugated antibodies and therefore permits visualization of a target protein without having it fused to fluorescent proteins17. DAT expressing CAD cells were permeabilized and immunolabeled with a rat monoclonal antibody targeting the DAT N-terminus, followed by labeling with Alexa405 and Alexa647 conjugated secondary antibodies. Equivalent to what we observed for Dronpa-DAT, the STORM images revealed localizations that often formed irregular nanodomains that were not discernible in the TIRF-M images (Fig. 2a–d). Indeed, a DBSCAN analysis of the STORM data confirmed DAT clustering in the plasma membrane of the CAD cells (Fig. 2e, k) and showed that

![Fig. 2 Visualization of DAT by STORM in CAD cells. TIRF-M (a, c, f, h), STORM (b, d, g, i, m, o), and widefield (l, n) images of CAD cells transiently expressing DAT with or without cholesterol depletion with 5 mM mβCD. DAT was visualized by immunolabeling with primary DAT antibody and Alexa405-Alexa647 conjugated anti-rat secondary antibody. a, f TIRF-M view of DAT with (mβCD) or without cholesterol depletion (control). b, g Reconstructed STORM image of TIRF-M image in a or f. c, d, h, i Enlarged TIRF-M or STORM images corresponding to the boxed regions in a, b (control) or f, g (mβCD). e, j DBSCAN-based cluster map of the STORM images in d (control) and j (mβCD). Clustered localizations are shown by color-coding with non-clustered localizations in gray. k Fraction of particles (according to DBSCAN) clustered in nanodomains. Data are % of localizations in cluster (means ± s.e.m., *p < 0.05, unpaired two-tailed t-test). l–n Visualization of DAT expressing CAD cells using inclined illumination to visualize a cross section through the cell. l Widefield image, m reconstructed STORM image of widefield image in l. n, o Enlarged TIRF-M or STORM images corresponding to the boxed regions in l, m. Red arrows mark DAT clustered in nanodomains. Data are based on 14–16 cells from three independent experiments. Scale bars a, b, f, g, i, m 5 μm, c, e, h–j 500 nm, n, o 400 nm.
cholesterol depletion decreased the estimated fraction of DAT in clusters (Fig. 2f–k).

In addition to TIRF-M illumination, we also performed STORM on the CAD cells with inclined illumination enabling visualization of a cross section through the cell. This imaging protocol is especially important when imaging neurons that may not have larger surfaces adhering directly to the glass surface as required for useful TIRF-M data. The use of inclined illumination supported the same distribution pattern of DAT in CAD cells as that observed with TIRF-M illumination; that is, the reconstructed STORM images revealed a DAT immunosignal distributed into discrete well-defined but irregularly shaped nanodomains of various sizes along the plasma membrane (Fig. 2l–o).

DAT is localized to nanodomains in dopaminergic neurons. To assess the distribution of endogenously expressed DAT, we prepared cultures of dopaminergic neurons and employed a STORM protocol similar to that used for the CAD cells. By widefield microscopy, using inclined illumination to reduce background signal, we observed a diffuse DAT immunosignal in the neuronal somas with some larger clusters of intensified signal (Fig. 3a, b). The reconstructed STORM images showed a substantially better resolution with an overall uniform punctate distribution of the DAT signal, which is likely to represent DAT in various intracellular compartments, as we focus on a thin slice through the large dopaminergic soma (Fig. 3f, g). In general, we were unable to see a clear plasma membrane immunosignal in the somas, consistent with relatively low somatic plasma membrane levels of DAT and high levels of intracellular DAT5. Interestingly, we also observed round, often hollow, DAT-positive structures in the cytosol of the cell bodies with diameters of 100–200 nm (and thus of the same size as, e.g., clathrin-coated vesicles30), which could represent DAT-containing vesicles with the N-terminal tail and thus the antibody–fluorophore complex on the outside of the vesicle exposed to the cytosol (Fig. 3c, h).

In the network of neuronal extensions and varicosities along these extensions, the widefield images showed a strong DAT immunosignal that was relatively uniformly distributed with some clustered elements (Fig. 3d, e). The STORM images again revealed a more punctate DAT distribution with multiple discrete clusters along the extensions as well as in the varicosities, believed to equivalent to presynaptic transmitter release sites given the enriched presence of VMAT22 (Fig. 3i, j). These clusters are likely to represent DAT confined to nanodomains in the plasma membrane as the images often indicated two apparent, separated membrane sheets in the extensions (Fig. 3i). As an example, the cross-sectional line scan in Fig. 3k reveals a distance of ~125 nm between the two sheets shown in Fig. 3i.

A closer look at the extensions and varicosities showed that the DAT signal was clustered in irregular nanoscale domains remarkably similar to those observed by STORM and PALM in CAD cells with a median cluster size of ~70 nm in diameter (Fig. 3l, n). A DBSCAN analysis substantiated the strong DAT clustering in nanodomains along extensions and varicosities (Fig. 3m, o, p). The nanodomain distribution was further supported by a nearest-neighbor analysis31. If DAT is homogenously expressed, then the resulting artifact clusters would be of uniform density because the photoswitching is constant within in the image. However, the individual clusters did not have a uniform density but rather became denser at the center, strongly supporting a truly clustered distribution (Fig. 3q–t).

DAT nanodomain localization is cholesterol-dependent. To investigate if cholesterol also had an effect on endogenous DAT distribution, neurons were treated with mβCD before STORM imaging. Similar to what we observed in CAD cells, mβCD decreased the clustered distribution of the DAT localizations in both neuronal extensions and varicosities (Fig. 4a–h). This was supported by DBSCAN analysis showing a significant reduction in the fraction of DAT in clusters (Fig. 4m, n). Moreover, the mβCD treatment decreased the size of the clusters, as illustrated by plotting the cumulative cluster distribution as a function of cluster area (Fig. 4o, p). In contrast to cholesterol depletion, disruption of the cytoskeleton with CytB before fixation had no effect on DAT distribution (Fig. 4i–p). We also tested the effect of nystatin and, as in the CAD cells, we observed a decrease in DAT clustering further supporting a key role of cholesterol (Supplementary Fig. 5). The reduced clustering upon cholesterol depletion/sequestration was unlikely caused by redistribution of DAT away from the membrane. That is, we saw no change in the constitutive internalization of DAT in response to mβCD treatment, as determined by quantifying intracellular accumulation of DAT labeled with the fluorescent cocaine analog JHC 1-6432 (Supplementary Fig. 6). Note that JHC 1-64 only visualizes surfaces DAT and internalized DAT, and not the large total pool of cytosolic DAT seen in the STORM images. As a consequence, the amount of DAT present on the cell surface might be less apparent in the STORM images compared to the JHC-64 confocal images.

NMDA receptor activation reduces DAT nanodomain localization. We next tested whether the nanodomain distribution of DAT was subject to dynamic regulation. Dopaminergic neurons are tightly regulated by excitatory input via ionotropic glutamate receptors. For example, a single dose of cocaine can elicit NMDA-receptor-dependent long-term potentiation (LTP) at midbrain glutamatergic synapses onto dopaminergic neurons33, 34. Moreover, there is evidence for the presence of NMDA receptors on the axonal terminals of these neurons, and direct short-term stimulation (5 min) of the neurons with NMDA can increase burst firing35, 36. We stimulated accordingly our cultured neurons either with NMDA alone (20 μM) or together with the selective NMDA receptor antagonist AP5 (100 μM), before STORM imaging. Strikingly, the resulting STORM images showed a significant decrease in DAT nanodomain localization in response to NMDA in both extensions and varicosities. This effect was blocked by AP5, in agreement with a specific effect on the NMDA receptors (Fig. 5a–p). There was no effect on the cluster size in the extensions, however, in the varicosities the NMDA treatment, similar to the mβCD treatment, decreased the cluster size of DAT (Fig. 5o, p). Subsequently, we tested whether the effect was reversible, that is, we assessed whether a 1-h recovery period following the 5-min NMDA treatment would reverse the change in DAT distribution. Again, in this experiment when neurons were fixed immediately after NMDA treatment, we reproduced the clear reduction in DAT clustering compared to the untreated neurons. However, when the dopaminergic neurons were allowed to recover for 1 h after NMDA washout, DAT recovered the degree of clustering seen in the untreated cells (Fig. 5q). Hence, NMDA appears to dynamically regulate DAT clustering in a reversible manner.

DAT displays non-overlapping distributions with TH and VMAT2. We finally wanted to apply dual-color dSTORM imaging to compare the distinct distribution of DAT with other key proteins of dopaminergic neurons. First, we evaluated the labeling accuracy by dual-labeling DAT with two separate fluorophores species in the same sample, Alexa647 and CF568. For this dual labeling, we observed that, although a greater number of localizations was detected with Alexa647, many of the detections from
Fig. 3 Endogenous DAT is clustered in nanodomains in the extensions and varicosities of cultured dopaminergic neurons. **a**–**c** Cross-section views through dopaminergic cell body showing the DAT distribution in the soma in an overall view, the soma edge, and in intracellular vesicular structures. DAT was visualized by immunolabeling with primary DAT antibody and Alexa405-Alexa647-conjugated secondary antibody. **a**, **f** Widefield image and corresponding reconstructed STORM image in the cell body. **b**, **g** Widefield image and corresponding STORM image at the soma edge; **c**, **h** Enlarged widefield or STORM image corresponding to the boxed regions in **a**, **f**, visualizing DAT in a putative endocytic vesicle. Yellow arrows highlight the circular distribution of the DAT signal. **d**, **i** Widefield image and reconstructed STORM image in a representative extension with varicosities. **e**, **j** Enlarged widefield image and corresponding STORM image of extension and varicosity. **k** Cross-sectional profile along the boxed region in **j** showing the signal intensity as a function of the distance (µm). **l**, **m** STORM image and corresponding DBSCAN-based cluster map showing the degree of clustering of DAT in a representative varicosity. **n**, **o** STORM image and corresponding DBSCAN-based cluster map showing the degree of clustering of DAT in a representative extension. Clustered localizations are shown by color-coding with non-clustered localizations in gray. **p** DBSCAN-based quantification of the clustering of endogenous DAT in dopaminergic neurons in soma, varicosities and extensions. Data are % of localizations in cluster (means±s.e.m., ***p<0.001, one-way ANOVA and Bonferroni’s post-test). Data are from 16 to 32 images from six individual experiments. Red arrows mark DAT clustered in nanodomains. **q** Varicosity from image **n**, where the localizations are colored by the number of nearest neighbors within a 30 nm radius. **r**–**t** Example clusters of varied densities identified in image **q**, where the number of nearest neighbors within a 30 nm radius are identified by color and by position on the z axis. Scale bars **a**, **f** 1.5 µm, **b**, **d**, **g** 1 µm, **c**, **h**, **m** 200 nm, **e**, **j**, **n–q** 500 nm.
the two fluorophore species identified the same groups of DAT. This applied both to somas, where DAT appeared to be mainly in the cytosolic compartment, as also seen for the single color dSTORM images of DAT, and to extensions and varicosities, where DAT nanodomains along the presumed membrane were clearly resolvable (Supplementary Fig. 7). Importantly,

**Fig. 4** Cholesterol depletion impairs DAT nanodomain clustering in extensions and varicosities of dopaminergic neurons. a, c, e, g, i, k Representative STORM images showing DAT distribution in extensions and varicosities of dopaminergic neurons under control conditions (a, c), after cholesterol removal with 5 mM mβCD (e, g), or after actin depolymerization with 5 μg ml⁻¹ CytD (i, k). DAT was visualized by immunolabeling with primary DAT antibody and Alexa405-Alexa647-conjugated secondary antibody. b, d, f, h, j, l DBSCAN-based cluster maps of the DAT signal in a, c, e, g, i, k. Clustered localizations are shown by color-coding with non-clustered localizations in gray. m, n DBSCAN quantifications DAT nanodomain localization in dopaminergic neurons after cholesterol removal or actin depolymerization, showing m clustering in varicosities and n clustering in extensions. Data are fraction of localizations in clusters in % (means ± s.e.m., ***p < 0.001, one-way ANOVA and Bonferroni’s post-test). o, p Probability distribution of the cluster sizes in varicosities (o) and extensions (p) at control conditions (black) or after treatment with mβCD (red) or CytD (blue). Data are based on from 9 to 39 images from three individual experiments. Red arrows mark DAT clustered in nanodomains. Scale bars 500 nm.
Fig. 5 NMDA stimulation of dopaminergic neurons leads to decreased clustering of DAT. **a, c, e, g, i, k** Representative STORM images showing DAT distribution in extensions and varicosities of dopaminergic neurons under control conditions (**a, c**), after NMDA stimulation (5 min, 20 µM) (**e, g**), or after NMDA stimulation (5 min, 20 µM) in presence of the NMDA receptor antagonist AP5 (100 µM) (**i, k**). DAT was visualized by immunolabeling with primary DAT antibody and Alexa405-Alexa647-conjugated secondary antibody. **b, d, f, h, j, l** DBSCAN-based cluster maps of the DAT signal in **a, c, e, g, i, k**. Clustered localizations are shown by color-coding with non-clustered localizations in gray. **m, n** Quantifications, based on the DBSCAN, of DAT nanodomain localization in dopaminergic neurons after NMDA or after NMDA + AP5 showing **m** clustering in varicosities, and **n** clustering in extensions. Data are fraction of localizations in clusters in % (means ± s.e.m., ***p < 0.001, one-way ANOVA and Bonferroni’s post-test). **o, p** Probability distribution of the cluster sizes in varicosities (**o**) and extensions (**p**) at control conditions (black) or after NMDA (purple) or after NMDA + AP5 (green). Data are from 63 to 64 images from four individual experiments. Scale bar 200 nm. **q** Reversibility of NMDA-induced decrease in DAT nanodomain localization. Neurons were treated for 5 min with NMDA (purple) or vehicle (black) and fixed (treatment) or treated for 5 min with NMDA (purple) or vehicle (black) followed by a 1 h wash out before fixation (+1 h). Data are based on DBSCAN of the resulting STORM images and shown as fraction of localizations in clusters after NMDA as percentage of fraction of localizations in clusters at control conditions (means ± s.e.m., ***p < 0.001, two-way ANOVA and Bonferroni’s post-test). Data are from 146 images from two individual experiments. Scale bars 500 nm
applicability of EM when testing the effect of pharmacological treatments. However, the application of this technique to DAT in the present study demonstrates a substantial part of these obstacles has been overcome, as illustrated by the application of this technique to DAT in the present study. Although EM still offers superior resolution, technical difficulties and requirements for sample preparation challenge the applicability of EM when testing the effect of pharmacological and biochemical manipulations. Specifically, the low labeling efficiency of immunogold EM imaging makes the technique less suitable for investigating protein clustering in a quantitative manner.

In this study, we apply super-resolution microscopy to reveal and visualize a dynamic molecular distribution of DAT in dopaminergic neurons. Specifically, the super-resolution images revealed that DAT is not uniformly distributed in the plasma membrane, as seen with classical microscopy, but localized to multiple irregular clusters or “nanodomains.” The nanodomains were clearly seen in the neuronal extensions where they demarcated two separate membrane sheets only 100–150 nm apart, as well as they were strongly present in the varicosities that presumably represent presynaptic transmitter release sites. Corresponding to the cell bodies of the cultured neurons, we observed little apparent DAT signal in the plasma membrane, but a strong cytoplasmic DAT signal that may represent newly synthesized DAT in the ER and Golgi in agreement with previous findings.

The DAT nanodomains in the extensions and varicosities of the dopaminergic neurons were also seen upon expression of DAT in catecholaminergic CAD cells. In the CAD cells, the DAT nanodomains were visualized both by STORM, as in the neurons, and by PALM. Whereas STORM and dSTORM exploit secondary antibody-amplification together with a photoswitchable multi-emitter fluorophore, PALM is based on use of photoswitchable fluorescent protein fused to the protein of interest. In this case, Dropana fused to PALM. PALM can accordingly be performed on live cells without fixation and permeabilization. Moreover, the 1:1 stoichiometry between the fluorescent protein and the target protein abolishes putative artifacts derived from having more than one or less than one fluorophore attached to the target protein. The need for using a fusion protein in PALM prevents analysis of endogenously expressed proteins. STORM/ dSTORM, on the other hand, excels by allowing investigation of endogenously expressed proteins, but typically requires fixation and, if the epitope is intracellular, permeabilization. Importantly, we observed nanodomain distribution of DAT with STORM in the CAD cells as we did with live PALM, suggesting that fixation and permeabilization are not a problem for our observations. We should note, however, that the apparent fraction of DAT in clusters was higher according to our STORM observations. We should note, however, that the apparent discrepancy might relate to differences in the amount of blinking per fluorophore and the stoichiometry of the fluorophores to transporter, which in the DBSCAN analysis may lead to a higher estimated clustered fraction in STORM compared to PALM.

The confinement of DAT into nanodomains displayed a striking dependency on cholesterol. Both removal of cholesterol with mβCD or sequestering cholesterol with nystatin markedly reduced DAT nanodomain localization in neurons and CAD cells. This observation is not least interesting because the high-resolution structure of Drosophila DAT revealed a cholesterol-binding site on the surface of the transporter. In addition, cholesterol has been shown to regulate DAT function, as well as the lateral mobility of heterologously expressed DAT in the plasma membrane. It is thus tempting to suggest that cholesterol-dependent sequestration of DAT into nanodomains represents a spatial correlate of function governed by direct binding of cholesterol to the transporter. The influence of cholesterol on DAT nanodomains is moreover of interest in light of previous biochemical data, as well as biochemical data from this study, indicating that DAT, in heterologous cells and striatal tissue, segregates into detergent-resistant membrane fractions (membrane raft fractions) dependent on cholesterol. The nanodomain distribution of DAT could also have important implications in relation to findings suggesting that localization of DAT to membrane cholesterol-dependent rafts is important for amphetamine-induced dopamine efflux via DAT, and for regulation of transporter internalization. Even more intriguing and with potentially larger functional implications, we found that...
the cholesterol-dependent nanodomain distribution of DAT is sensitive in a reversible manner to activation of excitatory receptors, such as NMDA receptors. NMDA receptor activation on dopaminergic neurons is known to increase burst firing\(^43, 44\) and, on this background, it is tempting to suggest that reversible association to cholesterol-dependent nanodomains might represent a means by which the neuron rapidly can adjust transporter localization and availability on the nanoscale in order to adapt to neuronal activity.

Previous biochemical data have suggested a tight association between DAT, TH and VMAT2 containing synaptic vesicles\(^42, 43\). For example, it has been proposed that DAT and VMAT2 are physically linked together via the synaptic vesicle protein synaptogycin-3\(^43\). To our knowledge, the relative distribution of these proteins, however, has never been investigated at sub-diffacting resolution. Importantly, the present dual-color super-resolution experiments demonstrate a distribution of DAT that is clearly distinct from that of both VMAT2 and TH. TH, the rate-limiting enzyme in dopamine synthesis, showed an irregular distribution in the cytosol of both extensions and varicosities. In the varicosities, the clustered signal was often found immediately adjacent to, but not overlapping with, the DAT nanodomains. This supports close proximity, but not formation of larger co-complexes. For VMAT2, we found a strongly enriched signal in

---

**Fig. 6** Cross-section through the cell body, extensions and varicosities of dopaminergic neurons showing by dual-color dSTORM imaging the distinct distribution of tyrosine hydroxylase (TH) compared to DAT. DAT was visualized by immunolabeling and Alexa647-conjugated secondary antibody. TH was visualized by immunolabeling and CF568-conjugated secondary antibody. a Somatic distribution of DAT. b Somatic distribution of TH. c Merged image of a and b. d–f Enlarged STORM images corresponding to the boxes shown in a–c. g Distribution of DAT in extension with varicosity. h Distribution of TH in extension with varicosity. i Merged image of g and h. j Distribution of DAT in extension. k Distribution of TH in extension. l Merged image of j and k. m Distribution of DAT in varicosity. n Distribution of TH in varicosity. o Merge image of m and n. Scale bars: a–c 5 μm, g–i 2 μm, d–f, j–o 500 nm.

**Fig. 7** Cross-section through the cell body, extensions and varicosities of dopaminergic neurons showing by dual-color dSTORM imaging the distinct distribution of the vesicular monoamine transporter-2 (VMAT2) compared to DAT. DAT was visualized by immunolabeling and Alexa647-conjugated secondary antibody. VMAT2 was visualized by immunolabeling and CF568-conjugated secondary antibody. a Somatic distribution of DAT. b Somatic distribution of VMAT2. c Merged image of a and b. d–f Enlarged STORM images corresponding to the boxes shown in a–c. g Distribution of DAT in extension with varicosities. h Distribution of VMAT2 in extension with varicosities. i Merged image of g and h. j Distribution of DAT in extension with varicosities. k Distribution of VMAT2 in extension. l Merged image of j and k. m Distribution of DAT in varicosity. n Distribution of VMAT2 in varicosity. o Merge image of m and n. Scale bars: a–c 5 μm, g–i 2 μm, d–f, j–o 500 nm.
the varicosities with limited signal in the extensions, consistent with the varicosities representing presynaptic release sites. We also observed that the VMAT2 signal was more uniform than the TH signal in the varicosities and in several cases “polarized”, i.e., the signal was localized essentially to only one part of the varicosity. Nonetheless, similar to what we saw for TH, the VMAT2 signal was often immediately adjacent to, but again, not overlapping with the DAT signal, arguing against formation of larger co-complexes.

Still relatively few studies have explored super-resolution microscopy to visualize neuronal membrane proteins and to determine the varicosity. Nonetheless, similar to what we saw for TH, the signal was localized essentially to only one part of the varicosity. We were able to visualize in detail how DAT is dynamically segregated into nanodomains in dendrites and in heterologous PC12 cells but it was not assessed whether the clusters were dependent on cholesterol and/or the cytoskeleton. Yet other neuronal membrane proteins may not cluster such as the cannabinoid CB1 receptor, adopting a uniform presynaptic distribution in GABAergic interneurons.

In summary, the present study demonstrates the power of super-resolution microscopy to dissect the distribution of an important membrane transport protein in neurons. Specifically, we were able to visualize in detail how DAT is dynamically segregated into nanodomains in dendrites, such as presynaptic varicosities, which cannot be efficiently resolved by classical FM due to their small size. By revealing a striking cholesterol dependency and sensitivity to excitation input, our results introduce new means by which DAT function can be regulated by membrane lipids and neuronal activity on the nanoscale. Furthermore, our data represent an important framework for future studies aimed at further dissecting the dynamic molecular architecture of dopaminergic neurotransmission and how this might change in diseases characterized by dysfunction of the dopamine system.

Methods

DNA constructs. Dronpa was a kind gift from Dr. Atsushi Miyawaki Brain Science Institute, RIKEN, Japan. EGFP was cut out by the pEGFP-C1 vector (Clontech), using AgeI and BglII, and replaced with a PCR fragment encoding Dronpa to generate pDronpa-C1 (sense primer: TCCGCTAGCGCTACCGGTCGCCACCA TGAGTGTTAGTAAACCAAG; antisense primer: ACTTGTACAGCTTGGCCTG TCCGCTAGCGCTACCGGTCGCCACCA). pDNA3.1 into the KpnI and XbaI sites of the pDronpa-C1 generating pDronpa-DAT. The construct was verified by sequencing. Src15-Dronpa, consisting of the myristoylated N-terminus of p60 fused to Dronpa was synthesized by DNA 2.0 (Menlo Park, CA). For sucrose gradient fractionation experiments, we used hDAT encoded by a synthetic gene kindly provided by Dr. Jonathan Javitch, Columbia University, NY, USA.

Cell culture. CAD (purchaseable from Sigma, 08100805) cells were grown in media containing Ham’s F12 and DMEM (1:1) (GIBCO, Grand Island, NY) and 10% (v/v) fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA) and 1% (v/v) penicillin/streptomycin (v/v), in 5% CO2 and 95% humidified atmosphere at 37 °C. Cells were transfected 48 h prior to experiments in a 1 μg/μl Lipo- fectamine 2000 (Invitrogen) ratio according to manufacturer’s protocol. The cells were regularly tested for mycoplasma with a standard mycoplasma test kit (Lonza, NJ, USA).

Dopamine uptake. One day prior to the experiment, 100,000 transiently transfected CAD cells were seeded in 24 well plates (TPP, Trasadingen Switzerland). On the day of the DAT assay, the cells were incubated in a HEPES buffered saline (HBS) (25 mM HEPES, 120 NaCl, 5 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 1 mM ascorbic acid, 5 mM D-glucose and 1 μM R041-0960 (COMT inhibitor) pH 7.4. Subsequently the cells were incubated for 3 min at room temperature with a serial dilution from 6.4 to 0.05 μM H-DA (2,5,6,7-[3H]-DA 52.8 – 61.4 Ci mmol−1)/mM PerkinElmer Life and Analytical Sciences, Boston, MA). Uptake was measured using Optiphase HSafe 3 scintillation fluid (PerkinElmer Life and Analytical Sciences).

Dissection and culturing of dopaminergic neurons. Dopaminergic neurons from the ventral midbrain were isolated using a protocol modified from Rayport et al. The ventral tegmental area and substantia nigra were located and isolated from 8 to 10 P2 Wistar rats (Charles River, Germany) and dissolved in a papain solution (116 mM NaCl, 5.4 mM KCl, 26 mM NaHCO3, 2 mM NaH2PO4, 1 mM MgSO4, EDTA, 25 mM glucose 1 mM cyansteine, 0.5 mM Kyrunate, and Papain 20 U/ml) for 25 min at 37 °C. The tissue was gently triturated to a single cell suspension by mechanical force and spun for 10 min at 100 × g, and seeded in warm SFIC [50% (v/v) modified Eagle’s medium (MEM), 40% (v/v) Dulbecco’s modified eagles medium (DMEM), 10% (v/v) F-12 (all from Invitrogen) supplemented with 1% (v/v) heat inactivated calf serum (FBS, 2.5 mg/ml), (Invitrogen), 0.35% (w/v) D-glucose, 0.5 mM glutamine, 5 mM Kyrunic acid, Penicillin, Streptomycin, liquid catalse (0.05%), and DiPorzio61 (containing insulin, transferrin, superoxide dismutase, protergestone, cortisol, Na2SeO4, and T3)] on Poly-d-Lysine coated, 1 M KOH sonicated coverslips with a thickness of 160–180 μm for STORM imaging or on a gla cell monolayer on coverslips for internalization experiments. Two hours after seeding, the cells were treated with 10 μg ml−1 gla derived neurotrophic factor (GDNF). 5-Fluorodeoxyuridine was added to the cell media at 6–7 DIV in order to inhibit cell proliferation of gla cells. The sample was used after 8–11 DIV.

Antibody labelling. Antibodies were labeled using a protocol described in Bates et al. The antibody (63 μg) was incubated for 40 min while shaking at room temperature with 100 mM NaHCO3, Alexa647 (17 μg ml−1), Alexa405 (50 μg ml−1) (Invitrogen, Carlsbad, Germany), or CF568 (Biotium, Freemont, CA) in a total volume of 60 μl in PBS and afterwards mixed with 140 μl PBS on a NAP-5 column (GE Healthcare) to isolate conjugated antibody-fluorophore complexes. All fluorophore-conjugated antibodies used were tested in order to keep the relative levels of fluorophoresantibody steady. For single color DAT labeling the Alexa405: Alexa647/antibody ratio was [2,3]:[0–8–0.9]:1. For dual color dSTORM the Alexa647/antibody or CF568/antibody ratio was [0–8–0.9]:1.

Immunocytochemistry. To assess the role of cholesterol and the cytoskeleton, dopaminergic neurons or transfected CAD cells were treated with 5 mM methyl-β-cyclodextrine (mβCD) for 30 min, 10 μg ml−1 nystatin for 20 min or 5 μg ml−1 cytochalasin D (CytD) for 2 h in cell media at 37 °C. To investigate the effect of NMDA stimulation, the neurons were incubated for 9 min in imaging buffer with or without 100 μM of the NMDA receptor antagonist AP5 before treatment for 5 min at room temperature with imaging buffer (control), 20 μM NMDA in imaging buffer, or 100 μM AP5 and 20 μM NMDA in imaging buffer. Cells were fixed using 3% (w/v) paraformaldehyde (PFA) in PBS (Electron Microscopy Sciences, Pennsylvania, USA) and incubated in 50 mM NH4Cl (Sigma) to quench background fluorescence. The sample was blocked and permeabilized in PBS containing 0.5% (w/v) Gibco, 0.2% (w/v) Saponin (Sigma) in PBS, and subsequently incubated for 1 h in the appropriate primary antibody, DAT: rat anti-DAT (Millipore, mab369, Massachusetts, USA) 1:200; TH: rabbit anti-TH antibody (Invitrogen, OOPA1-04050) (1:1000), VMAT2: rabbit anti-VMAT2 antibody (1:2000) (a kind gift from Dr. Gary Miller, Emory University) followed by secondary antibody 5 μg ml−1 Donkey anti-Rat (Jackson ImmunoResearch, 712-005-150, Pennsylvania, USA) or Donkey anti-Rabbit (Jackson ImmunoResearch, 711-005-152) conjugated with indicated fluorophores. The sample was post-fixed in 3% PFA in PBS and stored cold in PBS.

Striatal synaptosomal preparations. Cortical sections (1.5 mm) were used to isolate the striatum from 9 to 11 weeks old mice. The tissue was homogenized in homogenization buffer (0.32 M sucrose, 4 mM HEPES, pH 7.4) using a motor driven Teflon pestle at 800 r.p.m. The membranes were isolated by a dual spin; 10,000 × g for 10 min at 4 °C to remove cell nuclei and 16,000 × g for 20 min at 4 °C to pellet the membranes and remove cytoplasm.

Sucrose gradient. CAD cells transiently expressing DAT, treated as explained above, or striatal synaptosome preparations from 9 to 11 weeks old mice were lysed in 1 ml lysis buffer (1% (w/v) Brij58 (w/v), protease inhibitor, and 0.2 mM PMSF in the gradient buffer (25 mM HEPES, 150 mM NaCl, pH 7.4) for 15 min on ice. A 14 ml continuous sucrose size gradient was made by mixing 1 ml sample in a 15 ml centrifuge tube (Beckman Coulter, California, USA) with 1 ml sucrose (80% (w/v) in grid buffer) and 2 ml continuous sucrose (20% (w/v) in grid buffer). On top of this a 12 ml 15–35% (w/v) continuous gradient was layered using a SG15 gradient maker (Hoefer, Massachusetts, USA). Subsequently the gradient was ultracentrifuged at
100,000 x g for 18 h in a Beckman SW28.1 rotor head (Beckman Coulter, USA) and fractionated into nine sections of 1.5 ml using a P1 pump. The samples were electronically resuspended in PBS, 0.02% (w/v) mercaptoethanol (Ria Trick-CH; pH 7.4, 50 mM NaCl, 0.1 mM EDTA and subsequently washed twice in ice-cold PBS. Samples were lysed and mixed for 20 min at 4 °C in lysis buffer (25 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.2 mM PMSF, protease inhibitor mixture (Roche Applied Science), and 5 mM N-ethylmaleimide) and afterwards centrifuged for 15 min at 16,000 g. We collected “total sample” from each sample and mixed with the same amount of 2X loading buffer (1% SDS, 2.5% β-mercaptoethanol, and 100 mM dithiothreitol). We pulled down the proteins labeled with biocytin over night at 4 °C using avidin beads and washed the samples four times in lysis buffer. The samples were centrifuged for 3 min at 3000 x g per wash. Each sample was mixed with 2X loading buffer and loaded on a 10% pre-cast gel (Bio-Rad), followed by western blotting and development as described under sucrose gradient. We utilized a mouse HRP-conjugated anti-β-actin antibody (Sigma, A3854) 1:20,000. Immunoreactivity was quantified using ImageJ. Statistical significance was determined by one-way ANOVA followed by Bonferroni’s multiple comparisons test.

**Reversible biotinylation assay.** Cells (400,000) transiently expressing DAT were seeded in six well plates 1 day prior to the experiment. On the day of the experiment, the cells were incubated for 30 min with 12 mg ml−1 sulfo-NHS-S-S-biotin in PBS on ice and washed twice in ice-cold 100 mM glycine in PBS to remove unbound sulfo-NHS-S-S-biotin. During the internalization period, the samples were treated with mPSCD or left untreated as described above. Two wells were kept on ice and one well was incubated for 30 min at 37 °C in cell media without FBS supplemented with 100 µg ml−1 leupeptin and 20 µg monesin. To strip the biotin from the surface all samples but the “total surface” sample were incubated twice for 20 min in 100 mM MesNa, 0.2% bovine serum albumin, 50 mM Tris-HCI, pH 8.8, 100 mM NaCl, 1 mM EDTA and subsequently washed twice in ice-cold PBS. Samples were lyzed and mixed for 20 min at 4 °C in lysis buffer (25 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.2 mM PMSF, protease inhibitor mixture (Roche Applied Science), and 5 mM N-ethylmaleimide) and afterwards centrifuged for 15 min at 16,000 g. We collected “total sample” from each sample and mixed with the same amount of 2X loading buffer (1% SDS, 2.5% β-mercaptoethanol, and 100 mM dithiothreitol). We pulled down the proteins labeled with biocytin over night at 4 °C using avidin beads and washed the samples four times in lysis buffer. The samples were centrifuged for 3 min at 3000 x g per wash. Each sample was mixed with 2X loading buffer and loaded on a 10% pre-cast gel (Bio-Rad), followed by western blotting and development as described under sucrose gradient. We utilized a mouse HRP-conjugated anti-β-actin antibody (Sigma, A3854) 1:20,000. Immunoreactivity was quantified using ImageJ. Statistical significance was determined by one-way ANOVA followed by Bonferroni’s multiple comparisons test.

**Internalization assay.** Cultured dopaminergic neurons were used at 11–13 DIV. DAT at the cell surface was labeled by washing the neurons once in ice-cold imaging buffer, and incubate for 20 min with 20 nM HCHI-64 at 4 °C. The neurons were subsequently washed once in 37 °C imaging buffer before incubation with control or 5 mM mPSCD in imaging buffer. After 30 min the cells were washed twice and incubated for 30 min in the imaging buffer at 37 °C before imaging. The images were sequentially acquired and measured the integrated signal from total soma signal as well as the signal from the internalized fraction and so forth. If a localization does not have at least 200 photons. For Alexa647 and CF658 (STORM) particles were imaged using the built-in dual-color dSTORM imaging, we acquired 10,000 cycles of one frame of 561 nm laser activation followed by one frame of 647 nm laser at 16 Hz per cycle. Shutter regulated the light path in order to separate the light between the frames. The 561 nm and 647 nm lasers were held constant at 0.6 and 1.1 kW cm−2, respectively, while a 405 nm laser was gradually increased to <0.1 kW cm−2 in order to gradually track the dyeing. 10,000 cycles of four consecutive frames (one activation frame and three consecutive imaging frames) were acquired with a cycle rate of 56 Hz. For single color dSTORM imaging, super-resolution images were constructed from 5000 frames, where the sample was subject to constant high intensity for 3000 ms and incremental low intensity for 100 ms. For dual-color dSTORM imaging, we acquired 10,000 cycles of one frame of 561 nm laser activation followed by one frame of 647 nm laser at 16 Hz per cycle. Shutter regulated the light path in order to separate the light between the frames. The 561 nm and 647 nm lasers were held constant at 0.6 and 1.1 kW cm−2, respectively, while a 405 nm laser was gradually increased to <0.1 kW cm−2 in order to gradually track the dyeing. Particles appearing in more than one frame was removed from consecutive frames and total only counted once. For Dronpa (live-PALM) particles were only fitted when having an 8× signal-to-noise ratio and filtered by having at least 200 photons. For Alexa647 and CF658 (STORM) particles were required a 10× signal-to-noise ratio and 1000 photons. The localization precision was calculated as described44 and the resolution was assessed using the Localization Microscopy Analyzer (LAMA)65, 66. For PALM imaging of Dronpa-DAT the localization precision was ~15 nm whereas we achieved a localization precision of ~7 nm for STORM imaging (Alexa647). For STORM images, LAMA indicated a resolution of ~ 65 nm. To correct for drift in the X/Y direction, we applied the built-in drift correction in the analysis tool NS-elements (NIKON). Using continuous bright particles as fiducial markers this corrects for drift occurring in the sample due to slow temporal acquisition.

**Super-resolution data analysis.** Particles were fitted using the built-in STORM module in NS-Elements (NIKON) using a least-squares fitting methods to the raw data. Particles appearing in more than one frame was removed from consecutive modules and total only counted once. For Dronpa (live-PALM) particles were only fitted when having an 8× signal-to-noise ratio and filtered by having at least 200 photons. For Alexa647 and CF658 (STORM) particles were required a 10× signal-to-noise ratio and 1000 photons. The localization precision was calculated as described44 and the resolution was assessed using the Localization Microscopy Analyzer (LAMA)65, 66. For PALM imaging of Dronpa-DAT the localization precision was ~15 nm whereas we achieved a localization precision of ~7 nm for STORM imaging (Alexa647). For STORM images, LAMA indicated a resolution of ~ 65 nm. To correct for drift in the X/Y direction, we applied the built-in drift correction in the analysis tool NS-elements (NIKON). Using continuous bright particles as fiducial markers this corrects for drift occurring in the sample due to slow temporal acquisition.

**Density-based clustering analysis of super-resolution data.** For the cluster analysis we used DBSCAN45. This density-based clustering algorithm searches for clusters by looking for number of localizations within a circle defined by its radius, ϵ, and its center, p. If the area of the circle contains more than a specified number of points (MinPts), a new cluster with p as a core object is created. Thus, the DBSCAN algorithm requires the definition of the two input parameters ϵ and MinPts. The algorithm then subsequently tests all the localizations found in the first cluster for having MinPts within a radius, ε, and assigns them to the cluster, and so forth. If a localization does not have at least 200 photons. We tested the values on our images to determine DBSCAN was adjusted that would allow more than one DAT protein with antibodies bound next to each other in the plasma membrane inside the cluster. MinPts was chosen based on an evaluation of number of points in smaller clusters in our images. For our super-resolution data we applied custom routines and flexible procedures for clustering (fpc) package for R. We filtered the images by removing the monomer fraction localization with (r = 60 and MinPts = 10). Secondly, we defined the cluster fraction (r = 30 and MinPts = 20) and generated cluster maps and assigned single colors to the individual clusters. For Dronpa-DAT data we defined the cluster fraction of r = 30 and MinPts = 5 (For nystatin experiments both control and nystatin treated cells were analyzed with MinPts = 3). We tested the values on our images to determine DBSCAN’s ability to assign meaningful clusters. For the statistical analysis of the data we applied either a student’s t-test or a one-way ANOVA combined with Bonferroni’s post test.

Cluster size was determined using custom written scripts. The cluster area was identified by first finding the convex hull of each cluster through Andrew’s monotone chain convex hull algorithm. The area was calculated from the convex hull localizations by Gauss’s area formula, also known as the shoelace algorithm or the polygon’s area formula.68 Finally, the cluster sizes were fitted using a lognormal distribution in Matlab 2015a (Matlab, Mathworks).

**Coordinate based co-localization analysis.** For the co-localization analysis of the dual-color DAT stainings, we used a coordinate based colocalization (CBC) method. For Dronpa-DAT staining, the obtained 5000 consecutive frames with a frame rate of 33 Hz to construct one image. The 488 nm excitation laser was held constant, 0.4 kW cm−2, during the capture of the image while the 560 nm activation laser was linearly increased to <0.8 kW cm−2. To assess the role of cholesterol and the cytoskeleton, CAD cells transiently expressing Dronpa-DAT were treated with mPSCD or CytD as described above.
analysis within the super-resolution quantification tool, LAMA\textsuperscript{65, 66}. This method of analysis utilizes the coordinate information from each localization, rather than the intensity of the signal, in order to determine how much a given biological signal is distributed in reference to a separate biological signal, and vice versa. Each localization is assigned a CBC value between –1 and 1 that is determined by the distribution of localizations arising from the same source and from the compared source. Final CBC values of 1 indicate that the localization is part of a heterogenous group that is not near any localizations from the other population. CBC values of –1 indicate that the localization is part of a homogenous group of localizations that is in the vicinity of the other localization population. This entire process was automated and completed through the LAMA tool\textsuperscript{66}.

**Nanocluster verification.** The validity of the nanocluster phenotype in the PALM studies was confirmed through the use of an analysis method published by Baumgart et al.\textsuperscript{24}. This approach requires a data set containing a large range of expression levels in order to discern true clustering vs. cluster artifacts from stochastic blinking. A cluster mask was first applied to each image, where each localization was used as the center for a Gaussian, and a threshold was applied to identify a binary cluster mask. The Gaussians had a standard deviation of 80 nm and were cut off at 40 nm from the center. These parameters were identified based off visual inspection. A threshold of 2.5 was utilized to identify clusters, as recommended in the publication of this method\textsuperscript{24}. From each image, the relative area covered by the cluster mask ($\eta$) and the normalized average density of localizations within the clusters ($\rho_i/\rho_0$) were found, and compared in order to verify true clustering. For comparison, the expected values for a random distribution, as found by Baumgart et al., are given by the equation:

$$\rho_i/\rho_0 = 1 + 1.4\eta^4.$$  
(1)

Data positively deviating from the line for a random distribution indicates that true nanoclusters are identified. The validity of the nanocluster phenotype in the STORM studies was supported by a nearest-neighbor analysis. Through an in-house written python script, the localizations were organized into a KDTree with the use of the python library scipy. Spatial. The number of other localizations present within a 30 nm radius from each localization was identified through this KDTree structure, and the values were indexed with the coordinates of each localization. Images utilizing nearest-neighbor analysis were constructed utilizing this number of neighbor value as the color index and/or as the z axis value in order to represent the density of the localizations within clusters.

**Statistical analyses.** Imaging experiments were in general carried out three times on multiple cells (numbers indicated for each experiments) to ensure reproducible effect sizes. Biochemical experiments were carried out at least three times to ensure reproducibility. To avoid any bias and to further increase reproducibility samples were purposely kept in random orders when performing stainings, treatments as well as microscopy. Data were analyzed using unpaired, two-tailed t-tests, one-way analysis of variance (ANOVA) or repeated measures two-way ANOVA, wherever appropriate. Bonferroni’s post-hoc test was performed following significance with an ANOVA. We tested for variance in data showing that no significant difference was observed between groups compared in the statistical tests. Prism software was used for statistical analysis (GraphPad Inc, Version 6, La Jolla, CA, USA). Data are presented as means ± S.E.M. Significance level was set at P < 0.05.

**Code availability.** Custom written codes used for the data analysis can be found at: https://github.com/GetherLab/Super-Resolution-Data-Analysis together with a description. For the analysis we have used a combination of the two programs R and Python. All parameters are explained above.

**Data availability.** The authors declare that all the data supporting the findings of this work are available with the article and its Supplementary Information files and available from the corresponding author upon reasonable request.

Received: 7 January 2016 Accepted: 27 July 2017

Published online: 29 September 2017

**References**

1. Kristensen, A. S. et al. SLC6 neurotransmitter transporters: structure, function, and regulation. *Pharmacol. Rev.* **63**, 585–640 (2011).
2. Torres, G. E., Gainetdinov, R. R. & Caron, M. G. Plasma membrane monoamine transporters: structure, regulation and function. *Nat. Rev. Neurosci.* **4**, 13–25 (2003).
3. Iversen, S. D. & Iversen, L. L. Dopamine: 50 years in perspective. *Trends Neurosci.* **30**, 188–197 (2003).
4. German, C. L., Baladi, M. G., McFadden, L. M., Hanson, G. R. & Fleckenstein, A. E. Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease. *Pharmacol. Rev.* **67**, 1005–1024 (2015).
5. Block, E. R. et al. Brain region-specific trafficking of the dopamine transporter. *J. Neurosci.* **35**, 12845–12858 (2015).
6. Nirenberg, M. J., Vaughan, R. A., Uhl, G. R., Kuhar, M. J. & Pickel, V. M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. *J. Neurosci.* **16**, 436–447 (1996).
7. Hong, W. C. & Amara, S. G. Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons. *FASEB J.* **27**, 2995–3007 (2013).
8. Eriksen, J. et al. Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. *J. Neurosci.* **29**, 6794–6808 (2009).
9. Richardson, B. D. et al. Membrane potential shapes regulation of dopamine transporter trafficking at the plasma membrane. *Nat. Commun.* **7**, 10423 (2016).
10. Eriksen, J., Jørgensen, T. N. & Geher, U. Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. *J. Neurochem.* **113**, 27–41 (2010).
11. Freed, C. et al. Dopamine transporter immunoreactivity in rat brain. *J. Comp. Neurosci.* **359**, 340–349 (1995).
12. Cremona, M. L. et al. Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. *Nat. Neurosci.* **14**, 469–477 (2011).
13. Sorkina, T., Caltagirone, J. & Sorkin, A. Flotillins regulate membrane mobility of the dopamine transporter but are not required for its protein kinase C dependent endocytosis. *Traffic* **14**, 709–724 (2013).
14. Adkins, E. M. et al. Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. *Biochemistry* **46**, 10484–10497 (2007).
15. Foster, J. D., Adkins, S. D., Lever, J. R. & Vaughan, R. A. Phorbol ester induced trafficking-independence regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. *J. Neurochem.* **105**, 1683–1699 (2008).
16. Betzig, E. et al. Imaging intracellular fluorescent proteins at nanometer resolution. *Science* **313**, 1642–1645 (2006).
17. Huang, B., Bates, M. & Zhuang, X. Super-resolution fluorescence microscopy. *Nat. Rev. Mol. Cell Biol.* **10**, 783–795 (2009).
18. Maglone, M. & Sigrist, S. J. Seeing the forest by tree: super-resolution light microscopy meets the neurosciences. *Nat. Neurosci.* **16**, 790–797 (2013).
19. Sauer, M. Localization microscopy coming of age: from concepts to biological impact. *J. Cell Sci.* **126**, 3505–3513 (2013).
20. Nienhaus, K. & Nienhaus, G. U. Where do we stand with super-resolution optical microscopy? *J. Mol. Biol.* **428**, 308–322 (2016).
21. Qi, Y., Wang, J. K., McMillian, M. & Chikaraishi, D. M. Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. *J. Neurosci.* **17**, 1217–1225 (1997).
22. Habuchi, S. et al. Reversible single-molecule photo-switching in the GFP-like fluorescent protein Dronpa. *Proc. Natl Acad. Sci. USA* **102**, 9511–9516 (2005).
23. Ashcroft, D. Cell substrate contacts illuminated by total internal reflection fluorescence. *J. Cell Biol.* **89**, 141–145 (1981).
24. Baumgart, F. et al. Varying label density allows artifact-free analysis of membrane-protein nanoclusters. *Nat. Methods* **13**, 661–664 (2016).
25. Chichili, G. R. & Rodgers, W. Clustering of membrane raft proteins by the actin cytoskeleton. *J. Biol. Chem.* **282**, 36682–36691 (2007).
26. Mahammad, S. & Parmryd, I. Cholesterol depletion using methyl-beta-cyclodextrin. *Methods Mol. Biol.* **1232**, 91–102 (2015).
27. Rahbek-Clemmensen, T., Bay, T., Eriksen, J., Geher, U. & Jorgensen, T. N. The serotonin transporter undergoes constitutive internalization and is primarily sorted to late endosomes and lysosomal degradation. *J. Biol. Chem.* **289**, 23004–23019 (2014).
28. Jones, K. T., Zhen, J. & Reith, M. E. Importance of cholesterol in dopamine transporter function. *J. Neurochem.* **123**, 790–715 (2012).
29. Otto, G. P. & Nichols, B. J. The roles of flotillin microdomains—endocytosis and beyond. *J. Cell Sci.* **124**, 3933–3940 (2011).
30. Hansen, S. H., Sandvig, K. & van Deurs, B. The preendosomal compartment comprises distinct coated and noncoated endocytic vesicle populations. *J. Cell Biol.* **113**, 731–741 (1991).
31. Bar-On, D. et al. Super-resolution imaging reveals the internal architecture of nano-sized syntaxin clusters. *J. Biol. Chem.* **287**, 27158–27167 (2012).
32. Rickhag, M. et al. A C-terminal PDZ domain-binding sequence is required for striatal distribution of the dopamine transporter. *Nat. Commun.* **4**, 1580 (2013).
33. Saal, D., Dong, Y., Bonci, A. & Malenka, R. C. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. *Neuron* **37**, 577–582 (2003).
ARTICLE

34. Ungless, M. A., Whistle, J. L., Malenka, R. C. & Bonci, A. Single cocaine
exposure in vivo induces long-term potentiation in dopamine neurons. Nature
411, 583–587 (2001).
35. Paladini, C. A. & Roeppe, J. Generating bursts (and pauses) in the dopamine
midbrain neurons. Neuroscientist 282, 109–121 (2014).
36. Overton, P. & Clark, D. Iontophoretically administered drugs acting at the
N-methyl-D-aspartate receptor modulate burst firing in A9 dopamine neurons
in the rat. Synapse 10, 131–140 (1992).
37. Bates, M., Huang, B. & Zhuang, X. Super-resolution microscopy by nanoscale
localization of photo-switchable fluorescent probes. Curr. Opin. Chem. Biol. 12,
503–514 (2008).
38. Ciliax, B. J. et al. The dopamine transporter: immunochemical characterization
and localization in brain. J. Neurosci. 15, 1714–1723 (1995).
39. Pengtetsa, A., Wang, K. H. & Gouaux, E. X-ray structure of dopamine
transporter elucidates antidepressant mechanism. Nature 503, 85–90 (2013).
40. Hong, W. C. & Amara, S. G. Membrane cholesterol modulates the outward
conformation of the dopamine transporter and alters cocaine binding. J. Biol.
Chem. 285, 32616–32626 (2010).
41. Pizzo, A. B. et al. The membrane raft protein Flotillin-1 is essential in dopamine
neurons for amphetamine-induced behavior in Drosophila. Mol. Psychiatry 18,
824–833 (2013).
42. Cartier, E. A. et al. A biochemical and functional protein complex involving
dopamine synthesis and transport into synaptic vesicles. J. Biol. Chem. 285,
1957–1966 (2010).
43. Egana, L. A. et al. Physical and functional interaction between the dopamine
transporter and the synaptic vesicle protein synaptogyrin-3. J. Neurosci. 29,
4592–4604 (2009).
44. Blom, H. et al. Spatial distribution of DARPP-32 in dendritic spines. PLoS ONE
8, e75155 (2013).
45. Tonnesen, J., Katona, G., Rozsa, B. & Nagerl, U. V. Spine neck plasticity
regulates the organization of synapses. Nat. Neurosci. 17, 678–685 (2014).
46. Nair, D. et al. Super-resolution imaging reveals that AMPA receptors inside
synapses are dynamically organized in nanodomains regulated by PSD95.
J. Neurosci. 33, 13204–13224 (2013).
47. Chazeau, A. et al. Nanoscale segregation of actin nucleation and elongation
factors determines dendritic spine protrusion. EMBO J. 33, 2745–2764 (2014).
48. Dani, A., Huang, B., Bergan, J., Dulac, C. & Zhuang, X. Super-resolution
imaging of chemical synapses in the brain. Neuron 68, 843–856 (2010).
49. Sigal, Y. M., Speer, C. M., Babcock, H. P. & Zhuang, X. Mapping synaptic input
fields of neurons with super-resolution imaging. Cell 163, 493–505 (2015).
50. Dudok, B. et al. Cell-specific STORM super-resolution imaging reveals
nanoscale organization of cannabinoid signaling. Nat. Neurosci. 18, 75–86
(2015).
51. Hoze, N. et al. Heterogeneity of AMPA receptor trafficking and molecular
interactions revealed by superresolution analysis of live cell imaging. Proc. Natl
Acad. Sci. USA 109, 17052–17057 (2012).
52. Zhang, J., Carver, C. M., Choveau, F. S. & Shapiro, M. S. Clustering and
functional coupling of diverse ion channels and signaling proteins revealed by
super-resolution STORM microscopy in neurons. Neuron 92, 461–478 (2016).
53. Sinnen, B. L. et al. Optogenetic control of synaptic composition and function.
Neuron 93, 646–660 e645 (2017).
54. Ullrich, A. et al. Dynamical organization of syntaxin-1A at the presynaptic
active zone. PloS Comput. Biol. 11, e1004407 (2015).
55. Shrivastava, A. N. et al. Alpha-synuclein assemblies sequester neuronal alpha3-
Na+/K+ATPase and impair Na+ gradient. EMBO J. 34, 2408–2423 (2015).
56. Blom, H. et al. Spatial distribution of Na+/K+-ATPase in dendritic spines
dissected by nanoscale superresolution STED microscopy. BMC Neurosci. 12,
16 (2011).
57. MacGillivray, H. D. & Blanpied, T. A. Single-molecule tracking photoactivated
localization microscopy to map nano-scale structure and dynamics in living
spines. Curr. Protoc. Neurosci. 2, 20 20 21–22 20 19 (2013).
58. Ando, R., Mizuno, H. & Miyawaki, A. Regulated fast nucleocyttoplasmic
shuttling observed by reversible protein highlighting. Science 306, 1370–1373
(2004).
59. Loeland, C. J., Granas, C., Javitch, J. A. & Gether, U. Identification of
intracellular residues in the dopamine transporter critical for regulation of
transporter conformation and cocaine binding. J. Biol. Chem. 279, 3228–3238
(2004).
60. Rayport, S. et al. Identified postnatal mesolimbic dopamine neurons in culture:
morphology and electrophysiology. J. Neurosci. 12, 4264–4280 (1992).
61. di Porzio, U., Daguet, M. C., Glowinski, J. & Prochiantz, A. Effect of striatal
cells on in vitro maturation of mesencephalic dopaminergic neurons grown in
serum-free conditions. Nature 288, 370–373 (1980).
62. Bates, M., Huang, B., Dempsey, G. T. & Zhuang, X. Multicolor super-resolution
imaging with photo-switchable fluorescent probes. Science 317, 1749–1753
(2007).
63. Ciliberto, R. A. et al. Immunohistochemical localization of vesicular monoamine
transporter 2 (VMAT2) in mouse brain. J. Chem. Neuroanat. 83–84, 82–90
(2016).
64. Thompson, R. E., Larson, D. R. & Webb, W. W. Precise nanometer localization
analysis for individual fluorescent probes. Biophys. J. 82, 2775–2783 (2002).
65. Malkusz, S. et al. Coordinate-based colocalization analysis of single-molecule
localization microscopy data. Histochem. Cell Biol. 137, 1–10 (2012).
66. Malkusch, S. & Heilemann, M. Extracting quantitative information from single-
molecule super-resolution imaging data with LAMA-localization microscopy
analyzer. Sci. Rep. 6, 34488 (2016).
67. Ester, M., Kriegl, H.-P., Sander, J. & Xu, X. in Proc. 2nd International
Conference on Knowledge Discovery and Data Mining 226–231 (AAAI Press,
1996).
68. Andrews, A. M. Another efficient algorithm for convex hulls in two
dimensions. Inf. Process. Lett. 9, 216–219 (1979).

Acknowledgements
We thank Anette Dencker Kaas for excellent technical assistance. We thank Dr. Amy H.
Newman for providing HJC 1-64. The work was supported by the National Institute of
Health Grants P01 DA12408 (UG), the UNIK Center for Synthetic Biology (UG),
Lundbeck Foundation Center for Biomembranes in Nanomedicine (UG), the Danish
Council for Independent Research—Medical Sciences (UG, FHH), The Faculty of Health
and Medical Sciences, University of Copenhagen (Ph.D. fellowship to T.R.-C.) and the
Novo Nordisk Foundation (UG).

Author contributions
T.R.-C. and M.D.L. conducted all the experiments with help from M.A. T.R.-C., J.E.,
F.V., T.N.I., F.H.H. and U.G. designed the experiments. T.R.-C., M.D.L., S.E. and U.G.
analyzed the data. T.R.-C., M.D.L., S.E., F.H.H. and U.G. wrote the manuscript.

Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-00790-3.

Competing interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licences/by/4.0/.

© The Author(s) 2017